Graham Mould

Publications (2)5.92 Total impact

• Article: Quantitative assessment of the hepatic pharmacokinetics of the antimicrobial sitafloxacin in humans using in vivoF magnetic resonance spectroscopy.

  Geoffrey S Payne, David J Collins, Peter Loynds, Graham Mould, Philip S Murphy, Andrzej S K Dzik-Jurasz, Preminda Kessar, Nazneen Haque, Masayuki Yamaguchi, Shogo Atarashi, Martin O Leach
  [show abstract] [hide abstract]
  ABSTRACT: To measure hepatic concentrations of the fluorine-containing antimicrobial, sitafloxacin, using in vivo(19)F magnetic resonance spectroscopy (MRS). Data were acquired from eight healthy subjects at 2, 5, 8 and 24 h following doses of 500 mg day(-1) for 5 days using a (1)H/(19)F surface coil in a 1.5T clinical MR system. Tissue water was used as a reference. Estimated liver concentrations at 2 h were 15.0 +/- 4.0 microg ml(-1) (mean +/- 95% CI), compared with 3.54 +/- 0.58 microg ml(-1) in plasma (n = 6), and fell below threshold concentrations (2 microg ml(-1)) by 24 h. (19)F MRS is able to detect and quantify sitafloxacin in the liver. There was no evidence for the hepatic retention of the drug.
  British Journal of Clinical Pharmacology 03/2005; 59(2):244-8. · 2.96 Impact Factor
• Article: Quantitative assessment of the hepatic pharmacokinetics of the antimicrobial sitafloxacin in humans using in vivo19F magnetic resonance spectroscopy

  Geoffrey S. Payne, David J. Collins, Peter Loynds, Graham Mould, Philip S. Murphy, Andrzej S. K. Dzik-Jurasz, Preminda Kessar, Nazneen Haque, Masayuki Yamaguchi, Shogo Atarashi, Martin O. Leach
  [show abstract] [hide abstract]
  ABSTRACT: AimsTo measure hepatic concentrations of the fluorine-containing antimicrobial, sitafloxacin, using in vivo19F magnetic resonance spectroscopy (MRS).Methods Data were acquired from eight healthy subjects at 2, 5, 8 and 24 h following doses of 500 mg day−1 for 5 days using a 1H/19F surface coil in a 1.5T clinical MR system. Tissue water was used as a reference.ResultsEstimated liver concentrations at 2 h were 15.0 ± 4.0 µg ml−1 (mean ± 95% CI), compared with 3.54 ± 0.58 µg ml−1 in plasma (n = 6), and fell below threshold concentrations (2 µg ml−1) by 24 h.Conclusions19F MRS is able to detect and quantify sitafloxacin in the liver. There was no evidence for the hepatic retention of the drug.
  British Journal of Clinical Pharmacology 01/2005; 59(2):244 - 248. · 2.96 Impact Factor